Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 51 - Ovarian cancer

from Section 7 - Gynecological oncology

References

1. JemalA, BrayF, CenterMM, et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011;61:69–90.
2. World Health Organization. World Health Statistics Annuals 1987–1992. Geneva: World Health Organization, 1992.
3. McGuireWP, BradyMF, OzolsRF. The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol 1999;10(Suppl 1):29–34.
4. LandisSH, MurrayT, BoldenS, WingoPA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–31.
5. SeidmanJD, KurmanRJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003;17:909–925.
6. WhittemoreAS, HarrisR, ItnyreJ. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212–1220.
7. AarnioM, SankilaR, PukkalaE, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214–218.
8. NarodSA, FoulkesWD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665–676.
9. PruthiS, GostoutBS, LindorNM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc 2010;85:1111–1120.
10. CramerDW, HarlowBL, WillettWC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989;2:66–71.
11. MettlinCJ, PiverMS. A case–control study of milk-drinking and ovarian cancer risk. Am J Epidemiol 1990;132:871–876.
12. CramerDW, GreenbergER, Titus-ErnstoffL, et al. A case–control study of galactose consumption and metabolism in relation to ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:95–101.
13. FathallaMF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 1972;27:751–768.
14. VennA, WatsonL, BruinsmaF, GilesG, HealyD. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586–1590.
15. NessRB, CramerDW, GoodmanMT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case–control studies. Am J Epidemiol 2002;155:217–224.
16. HankinsonSE, ColditzGA, HunterDJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:284–290.
17. VachonCM, MinkPJ, JanneyCA, et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology 2002;13:66–71.
18.[No authors listed]. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650–655.
19. NarodSA, DubeMP, KlijnJ, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. JNCI 2002;94:1773–1779.
20. BastRC, Jr., FeeneyM, LazarusH, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331–1337.
21. MannWJ, PatsnerB, CohenH, LoeschM. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. JNCI 1988;80:208–209.
22. SkatesSJ, XuFJ, YuYH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76(Suppl):2004–2010.
23. JacobsIJ, SkatesSJ, MacDonaldN, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207–1210.
24. CarterJR, LauM, FowlerJM, et al. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol 1995;172:901–907.
25. PartridgeE, KreimerAR, GreenleeRT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775–782.
26. BuysSS, PartridgeE, BlackA, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295–2303.
27. MenonU, Gentry-MaharajA, HallettR, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327–340.
28. National Institutes of Health Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow up. JAMA 1997;277:491–497.
29. FishmanDA, CohenL, BlankSV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;192:1214–1221; discussion 1221–1222.
30. LurainJR, PiverMS. Familial ovarian cancer. Gynecol Oncol 1979;8:185–192.
31. KauffND, SatagopanJM, RobsonME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–1615.
32. RebbeckTR, LynchHT, NeuhausenSL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–1622.
33. LevineDA, ArgentaPA, YeeCJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222–4227.
34. FinchA, BeinerM, LubinskiJ, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296:185–192.
35. ColganTJ, MurphyJ, ColeDE, NarodS, RosenB. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283–1289.
36. CrumCP, DrapkinR, MironA, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3–9.
37. GreeneMH, MaiPL, SchwartzPE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?Am J Obstet Gynecol 2011;204:19.e1–19.e6.
38. GrannVR, JacobsonJS, ThomasonD, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002;20:2520–2529.
39. AndersonK, JacobsonJS, HeitjanDF, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006;144:397–406.
40. RodriguezC, PatelAV, CalleEE, JacobEJ, ThunMJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460–1465.
41. American Congress of Obstetricians and Gynecologists. ACOG Committee Opinion No. 280: the role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100:1413–1416.
42. ImSS, GordonAN, ButtinBM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35–41.
43. GoffBA, MandelLS, MelanconCH, MuntzHG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705–2712.
44. GoffBA, MandelLS, DrescherCW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221–227.
45. MalkasianGD, Jr., KnappRC, LavinPT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341–346.
46. MooreRG, BrownAK, MillerMC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–408.
47. UelandFR, DesimoneCP, SeamonLG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011;117:1289–1297.
48. PratJ. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 2014;124:1–5.
49. ChiDS, Abu-RustumNR, SonodaY, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005;192:1614–1619.
50. PiverMS, BarlowJJ, LeleSB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978;52:100–104.
51. YoungRC, DeckerDG, WhartonJT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072–3076.
52. KosaryC. Cancer of the corpus uteri. In Ries LAG, YoungJL, KeelGE, et al. (eds.) SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001. Bethesda, MD: National Cancer Institute, 2007; pp. 133–144.
53. HoskinsWJ, McGuireWP, BradyMF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974–979; discussion 979–980.
54. VergoteI, De WeverI, TjalmaW, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431–436.
55. StoeckleE, ParavisP, FloquetA, et al. Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 2004;14:779–787.
56. HoskinsWJ, BundyBN, ThigpenJT, OmuraGA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159–166.
57. BristowRE, TomacruzRS, ArmstrongDK, TrimbleEL, MontzFJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–1259.
58. FaderAN, RosePG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873–2883.
59. HoffmanMS, GriffinD, TebesS, et al. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol 2005;193:582–586; discussion 586–588.
60. PaniciPB, MaggioniA, HackerN, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. JNCI 2005;97:560–566.
61. RungruangB, MillerA, RichardSD, et al. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease? A Gynecologic Oncology Group study. Gynecol Oncol 2012;124:53–58.
62. HamiltonCA, MillerA, MillerC, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:521–526.
63. MunkarahAR, HallumAV, III, MorrisM, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13–17.
64. CurtinJP, MalikR, VenkatramanES, BarakatRR, HoskinsWJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9–12.
65. LiuPC, BenjaminI, MorganMA, et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:4–8.
66. BristowRE, MontzFJ, LagasseLD, LeuchterRS, KarlanBY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278–287.
67. BristowRE, PalisBE, ChiDS, ClibyWA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 2010;118:262–267.
68. ChiDS, EisenhauerEL, ZivanovicO, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:26–31.
69. MemarzadehS, LeeSB, BerekJS, Farias-EisnerR. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003;13:120–124.
70. BristowRE, DuskaLR, LambrouNC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532–1540.
71. BristowRE, EisenhauerEL, SantillanA, ChiDS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104:480–490.
72. AxtellAE, LeeMH, BristowRE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25:384–389.
73. MooreKN, MoxleyKM, FaderAN, et al. Serous fallopian tube carcinoma: a retrospective, multi-institutional case–control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol 2007;107:398–403.
74. van der BurgME, van LentM, BuyseM, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629–634.
75. RosePG, NerenstoneS, BradyM. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease. A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2002;21:201a.
76. VergoteI, TropeCG, AmantF, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–953.
77. WinterWE, III, MaxwellGL, TianC, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621–3627.
78. JazaeriAA, LuK, SchmandtR, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53–59.
79. GershensonDM, SunCC, LuKH, et al. Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108:361–368.
80. Winter-RoachB, HooperL, KitchenerH. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 2003;13:395–404.
81. FriedlanderML, HedleyDW, SwansonC, RussellP. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282–290.
82. VergoteIB, KaernJ, AbelerVM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993;169:40–52.
83. RubinSC, BenjaminI, BehbakhtK, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413–1416.
84. ChetritA, Hirsh-YechezkelG, Ben-DavidY, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20–25.
85. LacourRA, WestinSN, MeyerLA, et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 2011;121:358–363.
86. RichardsonGS, ScullyRE, NikruiN, NelsonJH, Jr. Common epithelial cancer of the ovary (2). N Engl J Med 1985;312:474–483.
87. YoungRC, WaltonLA, EllenbergSS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021–1027.
88. BolisG, ColomboN, PecorelliS, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995;6:887–893.
89. TropeC, KaernJ, HogbergT, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000;11:281–288.
90. ColomboN, GuthrieD, ChiariS, et al. International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. JNCI 2003;95:125–132.
91. TrimbosJB, VergoteI, BolisG, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. JNCI 2003;95:113–125.
92. YoungRC, BradyMF, NiebergRK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a gynecologic oncology group study. J Clin Oncol 2003;21:4350–4355.
93. KojsZ, GlinskiB, ReinfussM, et al. Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer. Cancer Radiother 2001;5:5–11.
94. ChiaraS, ConteP, FranzoneP, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 1994;17:72–76.
95. SellA, BertelsenK, AndersenJE, StroyerI, PanduroJ. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 1990;37:367–373.
96. BellJ, BradyMF, YoungRC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432–439.
97. ChanJK, TianC, FlemingGF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:301–306.
98. MannelRS, BradyMF, KohnEC, et al. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2011;122:89–94.
99. CannistraSA. Cancer of the ovary. N Engl J Med 1993;329:1550–1559.
100. McGuireWP, HoskinsWJ, BradyMF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.
101. PiccartMJ, BertelsenK, JamesK, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. JNCI 2000;92:699–708.
102. MuggiaFM, BralyPS, BradyMF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106–115.
103. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505–515.
104. OzolsRF, BundyBN, GreerBE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–3200.
105. du BoisA, LuckHJ, MeierW, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. JNCI 2003;95:1320–1329.
106. VaseyPA, JaysonGC, GordonA, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. JNCI 2004;96:1682–1691.
107. International Collaborative Ovarian Neoplasm Group. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. Lancet 1998;352:1571–1576.
108. BookmanMA, BradyMF, McGuireWP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419–1425.
109. KatsumataN, YasudaM, TakahashiF, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331–1338.
110. AlbertsDS, LiuPY, HanniganEV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–1955.
111. MarkmanM, BundyBN, AlbertsDS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–1007.
112. ArmstrongDK, BundyB, WenzelL, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.
113. SpriggsDR, BradyMF, VaccarelloL, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:4466–4471.
114. GreerBE, BundyBN, OzolsRF, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol 2005;99:71–79.
115. MarkmanM, LiuPY, WilczynskiS, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–2465.
116. BookmanMA, DarcyKM, Clarke-PearsonD, BoothbyRA, HorowitzIR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283–290.
117. HurteauJA, BlessingJA, DeCesareSL, CreasmanWT. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2001;82:7–10.
118. SchilderRJ, SillMW, ChenX, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11:5539–5548.
119. BurgerRA, SillMW, MonkBJ, GreerBE, SoroskyJI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165–5171.
120. SchilderRJ, SillMW, LeeRB, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26:3418–3425.
121. MateiD, SillMW, LankesHA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011;29:69–75.
122. GarciaAA, SillMW, LankesHA, et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2011;124:569–574.
123. ModesittSC, SillM, HoffmanJS, for the Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;109:182–186.
124. BehbakhtK, SillMW, DarcyKM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011;123:19–26.
125. UshaL, SillMW, DarcyKM, et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 2011;121:455–461.
126. FriedlanderM, HancockKC, RischinD, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32–37.
127. MatulonisUA, BerlinS, IvyP, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601–5606.
128. BiagiJJ, OzaAM, ChalchalHI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22:335–340.
129. BurgerRA. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group Study. In 46th Annual Meeting of the American Society of Clinical Oncology. Chicago, June, 2010.
130. PerrenT. ICON7: A phase III randomized gynecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). In ESMO Congress, 2010 (http://www.ctu.mrc.ac.uk/icon7/content_pages/documents/ICON7_%20ESMO%20Presidential%20Presentation.pdf, accessed 1 February 2014).
131. KristensenG. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Proc Am Soc Clin Oncol 2011;29(Suppl):333S.
132. LambertHE, RustinGJ, GregoryWM, NelstropAE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 1993;11:440–448.
133. Sorbe B for the Swedish-Norwegian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003;13:278–286.
134. GadducciA, ZolaP, LandoniF, et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995;58:42–47.
135. RustinGJ, van der BurgME, GriffinCL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155–1163.
136. ZangRY, HarterP, ChiDS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 2011;105:890–896.
137. MarkmanM, HoskinsW. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992;10:513–514.
138. CantuMG, BudaA, ParmaG, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002;20:1232–1237.
139. MonkBJ, HerzogTJ, KayeSB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107–3114.
140. ParmarMK, LedermannJA, ColomboN, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–2106.
141. Pujade-LauraineE, WagnerU, Aavall-LundqvistE, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323–3329.
142. PfistererJ, PlanteM, VergoteI, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699–4707.
143. AghajanianC, BlankSV, GoffBA, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039–2045.
144. MarkmanM, BookmanMA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26–35.
145. VergoteI, FinklerN, del CampoJ, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009;45:2324–2332.
146. RosePG, TianC, BookmanMA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;117:324–329.
147. StocklerMR, HilpertF, FriedlanderM, for the AURELIA Investigators. Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). J Clin Oncol 2013;31(Suppl): Abstr 5542.
148. CardenCP, YapTA, KayeSB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010;22:473–480.
149. KonstantinopoulosPA, SpentzosD, KarlanBY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555–3561.
150. Abu-RustumNR, AghajanianC. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998;25:235–242.
151. SchumerST, CannistraSA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180–1189.
152. HomesleyHD, BundyBN, HurteauJA, RothLM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 1999;72:131–137.
153. KiyokawaT, YoungRH, ScullyRE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 2006;30:277–299.